scholarly journals GLP-1 based therapies and disease course of inflammatory bowel disease

2021 ◽  
pp. 100979
Author(s):  
Marie Villumsen ◽  
Astrid Blicher Schelde ◽  
Espen Jimenez-Solem ◽  
Tine Jess ◽  
Kristine Højgaard Allin
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Disease Course ◽  
Inflammatory Bowel

scholarly journals Predicting disease course in ulcerative colitis using stool proteins identified through an aptamer-based screen

2021 ◽  
Vol 12 (1) ◽  
Author(s):  
Sanam Soomro ◽  
Suresh Venkateswaran ◽  
Kamala Vanarsa ◽  
Marwa Kharboutli ◽  
Malavika Nidhi ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Fecal Calprotectin ◽  
Disease Monitoring ◽  
Disease Course ◽  
Lipocalin 2 ◽  
Time Points ◽  
Inflammatory Bowel ◽  
Stool Samples

AbstractIn the search for improved stool biomarkers for inflammatory bowel disease (IBD), an aptamer-based screen of 1129 stool proteins was conducted using stool samples from an IBD cohort. Here we report that of the 20 proteins subsequently validated by ELISA, stool Ferritin, Fibrinogen, Haptoglobin, Hemoglobin, Lipocalin-2, MMP-12, MMP-9, Myeloperoxidase, PGRP-S, Properdin, Resistin, Serpin A4, and TIMP-1 are significantly elevated in both ulcerative colitis (UC) and Crohn’s disease (CD) compared to controls. When tested in a longitudinal cohort of 50 UC patients at 4 time-points, fecal Fibrinogen, MMP-8, PGRP-S, and TIMP-2 show the strongest positive correlation with concurrent PUCAI and PGA scores and are superior to fecal calprotectin. Unlike fecal calprotectin, baseline stool Fibrinogen, MMP-12, PGRP-S, TIMP-1, and TIMP-2 can predict clinical remission at Week-4. Here we show that stool proteins identified using the comprehensive aptamer-based screen are superior to fecal calprotectin alone in disease monitoring and prediction in IBD.

scholarly journals Sa1248 Late Adult-Onset Inflammatory Bowel Disease Patients Require Surgery Earlier During Their Disease Course Compared to Early Adult-Onset Patients

2012 ◽  
Vol 142 (5) ◽  
pp. S-253-S-254 ◽  
Author(s):  
Christina Y. Ha ◽  
Theodore M. Bayless ◽  
Alain Bitton ◽  
Judy H. Cho ◽  
Richard H. Duerr ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Disease Course ◽  
Adult Onset ◽  
Inflammatory Bowel

High and low body mass index may predict severe disease course in children with inflammatory bowel disease

2018 ◽  
Vol 53 (6) ◽  
pp. 708-713 ◽  
Author(s):  
Anat Yerushalmy-Feler ◽  
Amir Ben-Tov ◽  
Yael Weintraub ◽  
Achiya Amir ◽  
Tut Galai ◽  
...  
Keyword(s):  
Body Mass Index ◽  
Inflammatory Bowel Disease ◽  
Body Mass ◽  
Bowel Disease ◽  
Severe Disease ◽  
Disease Course ◽  
Low Body Mass Index ◽  
Inflammatory Bowel

scholarly journals Effect of Cognitive Behavioral Therapy on Clinical Disease Course in Adolescents and Young Adults With Inflammatory Bowel Disease and Subclinical Anxiety and/or Depression: Results of a Randomized Trial

2019 ◽  
Vol 25 (12) ◽  
pp. 1945-1956 ◽  
Author(s):  
Gertrude van den Brink ◽  
Luuk Stapersma ◽  
Anna Sophia Bom ◽  
Dimitris Rizopolous ◽  
C Janneke van der Woude ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Cognitive Behavioral Therapy ◽  
Disease Activity ◽  
Bowel Disease ◽  
Behavioral Therapy ◽  
Fecal Calprotectin ◽  
Clinical Disease ◽  
Disease Course ◽  
First Relapse ◽  
Inflammatory Bowel

Abstract Background Anxiety and depressive symptoms are prevalent in patients with inflammatory bowel disease (IBD) and may negatively influence disease course. Disease activity could be affected positively by treatment of psychological symptoms. We investigated the effect of cognitive behavioral therapy (CBT) on clinical disease course in 10–25-year-old IBD patients experiencing subclinical anxiety and/or depression. Methods In this multicenter parallel group randomized controlled trial, IBD patients were randomized to disease-specific CBT in addition to standard medical care (CBT + care us usual [CAU]) or CAU only. The primary outcome was time to first relapse in the first 12 months. Secondary outcomes were clinical disease activity, fecal calprotectin, and C-reactive protein (CRP). Survival analyses and linear mixed models were performed to compare groups. Results Seventy patients were randomized (CBT+CAU = 37, CAU = 33), with a mean age of 18.3 years (±50% < 18 y, 31.4% male, 51.4% Crohn’s disease, 93% in remission). Time to first relapse did not differ between patients in the CBT+CAU group vs the CAU group (n = 65, P = 0.915). Furthermore, clinical disease activity, fecal calprotectin, and CRP did not significantly change over time between/within both groups. Exploratory analyses in 10–18-year-old patients showed a 9% increase per month of fecal calprotectin and a 7% increase per month of serum CRP in the CAU group, which was not seen in the CAU+CBT group. Conclusions CBT did not influence time to relapse in young IBD patients with subclinical anxiety and/or depression. However, exploratory analyses may suggest a beneficial effect of CBT on inflammatory markers in children.

scholarly journals Inflammatory Bowel Disease in Children of Middle Eastern Descent

2014 ◽  
Vol 2014 ◽  
pp. 1-7 ◽  
Author(s):  
Christina Mai Ying Naidoo ◽  
Steven T. Leach ◽  
Andrew S. Day ◽  
Daniel A. Lemberg
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Middle Eastern ◽  
Control Group ◽  
Colonic Disease ◽  
Disease Course ◽  
Age And Gender ◽  
Inflammatory Bowel ◽  
And Gender ◽  
And Behavior

Increasing rates of inflammatory bowel disease (IBD) are now seen in populations where it was once uncommon. The pattern of IBD in children of Middle Eastern descent in Australia has never been reported. This study aimed to investigate the burden of IBD in children of Middle Eastern descent at the Sydney Children’s Hospital, Randwick (SCHR). The SCHR IBD database was used to identify patients of self-reported Middle Eastern ethnicity diagnosed between 1987 and 2011. Demographic, diagnosis, and management data was collected for all Middle Eastern children and an age and gender matched non-Middle Eastern IBD control group. Twenty-four patients of Middle Eastern descent were identified. Middle Eastern Crohn’s disease patients had higher disease activity at diagnosis, higher use of thiopurines, and less restricted colonic disease than controls. Although there were limitations with this dataset, we estimated a higher prevalence of IBD in Middle Eastern children and they had a different disease phenotype and behavior compared to the control group, with less disease restricted to the colon and likely a more active disease course.

Sign in / Sign up

Export Citation Format

Share Document